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Abstract
MAVIDOS is a randomised, double-blind, placebo-controlled trial (ISRCTN82927713, registered 2008 Apr 11), funded
by Arthritis Research UK, MRC, Bupa Foundation and NIHR.
Background: Osteoporosis is a major public health problem as a result of associated fragility fractures. Skeletal
strength increases from birth to a peak in early adulthood. This peak predicts osteoporosis risk in later life. Vitamin
D insufficiency in pregnancy is common (31% in a recent Southampton cohort) and predicts reduced bone mass
in the offspring. In this study we aim to test whether offspring of mothers supplemented with vitamin D in
pregnancy have higher bone mass at birth than those whose mothers were not supplemented.
Methods/Design: Women have their vitamin D status assessed after ultrasound scanning in the twelfth week of
pregnancy at 3 trial centres (Southampton, Sheffield, Oxford). Women with circulating 25(OH)-vitamin D levels 25-
100 nmol/l are randomised in a double-blind design to either oral vitamin D supplement (1000 IU cholecalciferol/
day, n = 477) or placebo at 14 weeks (n = 477). Questionnaire data include parity, sunlight exposure, dietary
information, and cigarette and alcohol consumption. At 19 and 34 weeks maternal anthropometry is assessed and
blood samples taken to measure 25(OH)-vitamin D, PTH and biochemistry. At delivery venous umbilical cord blood
is collected, together with umbilical cord and placental tissue. The babies undergo DXA assessment of bone mass
within the first 14 days after birth, with the primary outcome being whole body bone mineral content adjusted for
gestational age and age. Children are then followed up with yearly assessment of health, diet, physical activity and
anthropometric measures, with repeat assessment of bone mass by DXA at age 4 years.
Discussion: As far as we are aware, this randomised trial is one of the first ever tests of the early life origins hypothesis
in human participants and has the potential to inform public health policy regarding vitamin D supplementation in
pregnancy. It will also provide a valuable resource in which to study the influence of maternal vitamin D status on other
childhood outcomes such as glucose tolerance, blood pressure, cardiovascular function, IQ and immunology.
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Background
Osteoporosis: Epidemiology and impact
Osteoporosis is a skeletal disorder characterised by low
bone mass and micro-architectural deterioration of bone
tissue, which predisposes to fracture [1]. These fractures
typically occur at the hip, spine and wrist. It has been
estimated that the remaining lifetime risk of fracture at
age 50 years approaches 50% among women and 20%
among men [2]. In the UK, the annual cost to the
National Health Service of managing osteoporotic frac-
ture is £1.7 billion, with about 80% of this figure attribu-
table to hip fracture [3].
Early growth and later risk of fracture
Bone mass (a composite of size and volumetric density)
increases through early life and childhood/adolescence
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to a peak in early adulthood. The magnitude of this
“peak bone mass” is a strong predictor of later osteo-
porosis risk [4]. Cohort studies in adults from the UK,
USA, Australia and Scandinavia have shown that those
who were heavier at birth or in infancy have a greater
bone mass [5-8] and a reduced risk of fracture [9] in
later life. Mother-offspring studies have revealed that
factors such as maternal lifestyle, body build, diet and
physical activity during pregnancy may all influence off-
spring bone mineral accrual [10-12].
Maternal vitamin D insufficiency and offspring bone
mineral accrual
The specific micronutrient that appears to have the
greatest individual contribution, certainly for the devel-
oped world, is vitamin D. There are very few data on
vitamin D levels in pregnant women across a sample
representative of the UK; the available studies, however,
suggest that vitamin D insufficiency is common in this
group. In a Southampton pregnancy cohort, composed
of white Caucasians, 31% had concentrations of circulat-
ing 25(OH)-vitamin D lower than 50 nmol/l and 18%
less than 25 nmol/l [13]. A 2010 US study of a popula-
tion representative of the national demographic distribu-
tion revealed that 80% of black pregnant women had
levels less than 50 nmol/l; the figures for Hispanic and
white pregnant women were 45% and 13% respectively
[14]. In Asian cohorts in the northern hemisphere the
burden of insufficiency is even higher [15-19], possibly
reaching 90% or greater: A study of non-pregnant
South-Asian women in the North of England, many of
whom were of child-bearing age, demonstrated that 94%
had circulating levels of 25(OH)-vitamin D < = 37.5
nmo/l and 26% < = 12.5 nmol/l [20]. As the main
source of vitamin D for most people is synthesis in the
skin under the influence of UVB radiation from sun
light exposure, ethnicity, skin pigmentation, covering
and northerly latitudes (as in UK) are all major risk fac-
tors for insufficiency [21].
In the Southampton cohort [13], lower concentrations
of serum 25(OH)-vitamin D in mothers during late
pregnancy were associated with reduced whole-body
BMC and BMD in children at age 9 years, indepen-
dently of social class, diet and body size. Estimated
exposure to ultraviolet B radiation during late pregnancy
and the maternal use of vitamin D supplements both
predicted maternal 25(OH)-vitamin D concentration
and childhood bone mass. Adjunctive evidence support-
ing a role for maternal vitamin D status was obtained in
the Southampton Women’s Survey (SWS), where mater-
nal vitamin D concentrations correlated positively with
neonatal bone mass [22]. A 2009 study of the Avon
Longitudinal Study of Parents and Children [23] demon-
strated a positive association between ambient
ultraviolet B radiation in pregnancy and offspring BMC
at 9 years, further supporting the notion that maternal
vitamin D status is an important determinant of off-
spring bone development. Furthermore, high resolution
ultrasound measurements of pregnancies in the SWS
cohort have revealed that changes in distal femoral mor-
phology (increased splaying of the metaphysis relative to
its length, reminiscent of changes observed in postnatal
rickets) are associated with low circulating concentra-
tions of 25(OH)-vitamin D in the mother as early as 19
weeks gestation [24]. The effect of maternal 25(OH)-
vitamin D status appeared to be partly mediated via
concentrations of venous umbilical cord calcium, sug-
gesting that placental calcium transfer to the fetus may
be a critical step in these associations. Indeed mRNA
expression of an active placental calcium ATPase posi-
tively predicted offspring BMC in SWS neonates [25].
Previous trials of vitamin D supplementation in
pregnancy
There have been several, mainly small, intervention studies
examining this issue [16-19,26,27], but only one has exam-
ined bone mass at birth [28]. In this study bone mass of
offspring born to 19 Asian mothers who had taken 1000
international units of vitamin D daily through pregnancy
was compared with that of babies born to 45 control
mothers using single photon absorptiometry. The small
participant numbers and technique used to assess bone
mineral mean that it is difficult to draw any definite con-
clusions from negative results of this study. These studies
suggest that daily doses of 1000 IU cholecalciferol or
higher doses as a bolus appear to be safe, at least in the
short term. National guidance has been rather conflicting
over recent years, with both Cochrane [29] and NICE
(CG62 http://www.nice.org.uk/nicemedia/live/11947/
40115/40115.pdf) reviews concluding that there was insuf-
ficient evidence on which to base a firm recommendation;
the latter suggested supplementation with 400 IU daily for
high risk groups. The UK Scientific Advisory Committee
on Nutrition (SACN), building on previous recommenda-
tions from the Committee on Medical Aspects of Food
and Nutrition Policy (COMA)[30], reviewed the area in
2007 http://www.sacn.gov.uk/pdfs/sacn_position_vita-
min_d_2007_05_07.pdf and DH, in The Pregnancy Book
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digita-
lassets/@dh/@en/@ps/@sta/@perf/documents/digitalas-
set/dh_107667.pdf now advise all women to take 400 IU
cholecalciferol daily. It is unclear how well these guidelines
are currently followed in the UK however, but anecdotal
evidence suggests that take up has been low.
Aim
To test the hypothesis that vitamin D supplementation
during pregnancy of women who have low levels of
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vitamin D will result in improved neonatal bone mineral
content when compared with offspring of women who
were not supplemented.
Study design
MAVIDOS is a randomised, double-blind, placebo con-
trolled trial, comparing 1000 IU cholecalciferol orally
daily with matched placebo in pregnant women from 14
weeks gestation until delivery of the baby, with neonatal
whole body bone mineral content, assessed by DXA, as
the primary outcome.
Methods (Figure 1)
Recruitment
Information about the trial is displayed as posters in
general practice surgeries and maternity hospital waiting
areas. An information sheet outlining the study is sent
out to each woman with the letter for the screening
appointment for nuchal lucency or initial dating scan (at
around 12 weeks gestation). Information is translated
into other languages where possible, to maximise parti-
cipation by ethnic minorities. A research nurse
approaches the women whilst they wait for the screen-
ing ultrasound scan, involving an interpreter if required
and available. If informed consent for participation in
the study is gained, a blood sample for 25(OH)-vitamin
D is taken along with the standard Down’s screening
bloods or alone if only a dating scan is being performed.
Screening 25(OH)-vitamin D concentration
Circulating 25(OH)-vitamin D is measured locally; all
three laboratories (Southampton, Oxford, Sheffield) par-
ticipate in DEQAS vitamin D quality assurance system
http://www.deqas.org/. Women with circulating levels of
less than 25 nmol/l are excluded from the trial (pre-ran-
domisation) and results are forwarded to their general
practitioners in order that vitamin D supplementation
can be prescribed. The general practitioner is advised to
start either one Healthy Start Vitamin daily if available,
or a prescribed calcium and vitamin D supplement
yielding the same daily dose of cholecalciferol (400 IU).
The general practitioner is also advised to recheck the
25(OH)-vitamin D level at the 34 week blood tests.
Likewise, women with circulating levels of greater than
100 nmol/l are excluded. Those women whose circulat-
ing 25(OH)-vitamin D falls between 25 nmol/l and 100
nmol/l are randomised to an oral vitamin D supplement
(1000 IU cholecalciferol per day) or matched placebo
from 14 weeks (or as soon as possible after obtaining 25
(OH)-vitamin D status if participant is enrolled at
greater than 12 weeks gestation) to delivery in a double-
blind randomised trial design. At the initial recruitment,
participants are given a urine collection bottle and
instructions on collecting a second void urine (for bone
turnover markers) to bring to the 14 week assessment.
14 week assessment
Women recruited are assessed at 14 weeks gestation (or
as soon as possible after obtaining 25(OH)-vitamin D
status up to 17 weeks if enrolled at greater than 12
weeks gestation), either at home or in the research
clinic. Here, study medication is issued and an inter-
viewer-led questionnaire is administered to gather infor-
mation on parity, baseline demographics, smoking,
alcohol intake, calcium and vitamin D dietary intake,
exercise, health, sunlight exposure and medication. A
subgroup of women (n = 50) are invited to wear a sun-
light exposure badge, incorporating a polysulphone film,
which changes its composition according to ultra-violet
exposure, for one week to validate the sunlight exposure
questionnaire data. Height, weight, skin fold thickness
(triceps, biceps, subscapular and suprailiac) and grip
strength are measured. Inter-observer variation (IOV)
studies will be performed in each centre, after central
training according to the study protocol. A further
blood sample is taken and plasma is stored at -80°C for
measurement of 25(OH)-vitamin D, vitamin D binding
protein (DBP), calcium, bone specific alkaline phospha-
tase and albumin centrally (MRC Human Nutrition
Research, Cambridge, UK) at the end of the study. If
consent for genetic analyses is obtained, blood pellets
for later DNA extraction are stored. Where the baby’s
father attends at either the 14 or 34 week visit, their
height is measured.
Randomization and issue of Investigational Medicinal
Product (IMP)
The IMP and matched placebo are manufactured by Bil-
care GCS (Europe) Ltd, Waller House, Elvicta Business
Park, Crickhowell, Powys NP8 1DF, UK. The manufac-
turers had no role in the trial other than supply of the
randomised IMP. The IMP capsule contains 1000
Mothers recruited n=1600Weeks 
gestation
12/40
Randomisation n=1200
Central 25D, biochem
Placebo n=600
Anthropometry, DXA
n=477 each arm
Check 25D, 
ALP, Ca, Albumin
Birth
14/40
Repeat 25D, biochem, 3D 
ultrasound scan34/40
25D > 100 nmol/l
Ineligible
n=100
25nmol/l < 25D < 100nmol/l
D3 1000 iu daily n=600
25D < 25 nmol/l
Supplementation
n=300
19/40 3D ultrasound scan
MAVIDOS Maternal Vitamin D Osteoporosis Trial
Mothers invited n=3200
Repeat 25D, biochem, 3D 
ultrasound scan
3D ultrasound scan
Refuse: n=1600
Miscarriage, 
withdrawal, loss to 
follow up:
n=123 each group
Figure 1 MAVIDOS trial outline, showing expected recruitment
and withdrawal through study. Timings are given relative to the
40 week normal gestation.
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international units of cholecalciferol (vitamin D3), with
excipients matched to the placebo capsule. The dose
was chosen with the aim of achieving repletion without
causing supranormal circulating levels of 25(OH)-vita-
min D [31]. The medication is blister packed in a single
box for each woman for the duration of pregnancy.
Study medication (active/placebo) is supplied to the
local pharmacy pre-randomised by the manufacturer
(1:1, unstratified by centre) and sequentially numbered
for storage and dispensing. Code break envelopes are
supplied to the lead pharmacist, but are not available to
the investigative team. Emergency code break access is
available through the local principal investigator and on-
call pharmacist. A single pack for each participant is
issued sequentially (containing all pills for duration of
the study). Each pack is individually prescribed for each
participant. The trials pharmacist allocates a pack to
that prescription, documenting both the pack number
and the MAVIDOS participant ID; these are checked
again by the research nurse on collection, and documen-
ted in the participant’s notes; the medication pack
comes with a tear-off adhesive label, which is placed in
the participant’s notes as an added safeguard against
errors in pack allocation. The research nurse collects
the medication pack for all participants attending that
day and issues to the participants directly. A clear
sticker is applied to the front of participant obstetric
notes, alerting clinicians to the mother’s enrolment in
the study. An information sheet and one copy of the
consent form are filed in the participant’s notes. The
mother (with a copy for the father) is given contact
details for the study coordinator and the research nurse,
and asked to inform them immediately of commence-
ment of labour. A second urine collection bottle and
instructions on collecting a second void urine are issued,
to be brought to the 34 week assessment.
Anomaly/3D ultrasound scan at 18-21 weeks gestation
Participants return at 18-21 weeks gestation for a high
resolution 3D ultrasound scan to obtain detailed mea-
surements of the pregnancy http://www.bmus.org/poli-
cies-guides/SoR-Professional-Working-Standards-guide-
lines.pdf. The NHS anomaly scan is also performed at
this visit by a MAVIDOS ultrasonographer. Should any
abnormalities be identified, these participants are
referred to their local fetal medicine department for
further management and may be excluded from this
study. These findings will also be recorded as adverse
events and thus may inform potential new hypotheses
regarding the action of vitamin D in pregnancy. A pill
count is performed to assess compliance with the study
medication.
34 week visit and 3D ultrasound scan
At 34 weeks gestation (up to before admission for deliv-
ery) the mothers return to the research clinic, when
repeat blood samples for 25(OH)-vitamin D, DBP, cal-
cium, bone specific alkaline phosphatase and albumin
are taken. Assessments of maternal anthropometry, cal-
cium and vitamin D intake, smoking, alcohol, exercise,
medications and health are also repeated. Compliance
with the study medication is assessed by pill count. A
repeat growth and 3D ultrasound scan is performed
[32]. Any abnormalities noted on the scan are recorded.
The mother is given an information sheet about the
neonatal DXA assessment at this visit. Mothers receive
standard antenatal care and any woman found to be
hypercalcaemic (serum calcium > 2.75 mmol/l) will be
followed-up and managed appropriately.
Admission to hospital for labour
The study coordinator/research nurse is informed of any
woman entering labour by the NHS midwives, or by the
woman/partner themselves. Obstetric history is
recorded. The attending midwives collect venous umbili-
cal cord blood (including samples for genetic analyses)
and placental and umbilical cord tissue samples at deliv-
ery. After ensuring that the hips have been assessed and
cleared by a paediatrician, a research nurse measures
the baby’s anthropometric indices (length, weight, skin-
folds, head and abdominal circumference) and arranges
an appropriate time for the baby to undergo bone den-
sity assessment by DXA. She also issues the mother
with cotton wool balls, a collection pot and instructions
on collecting a urine sample from the baby. The urine
sample is then brought to the DXA appointment.
Neonatal DXA assessment
The reliability of DXA measurements in neonates has
been well documented in the Southampton Women’s
Survey [11]. The baby is pacified, fed, fully undressed
and then swaddled in a towel before placement on the
densitometer [Hologic Discovery instrument using pae-
diatric software (Hologic Inc., Bedford, MA, USA)]. The
scanner is calibrated against a spine phantom every day
together with daily quality assurance and periodic step-
wedge calibration all performed as per manufacturer’s
instructions (Hologic Inc., Bedford, MA, USA). If possi-
ble the baby is scanned whilst still an inpatient, other-
wise the mother returns within 14 days for assessment.
Whole body and lumbar spine bone area, bone mineral
content and bone mineral density are measured. Appro-
priate cross-calibration of DXA scanners between the 3
centres will be made with neonatal phantoms. Informa-
tion on pregnancy complications is collected from the
hospital notes. The total radiation dose (0.04 mSv) is
equivalent to around 2 day’s exposure to background
radiation in Cornwall (UK) or 7 day’s exposure in other
parts of the UK.
Maternal DXA assessment
To enable assessment of the influence of vitamin D
insufficiency and repletion on the maternal skeleton,
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consecutive participants are asked for consent to per-
form additional DXA assessment of the mother, using
the Hologic Discovery instrument, at the neonatal DXA
visit. An information sheet about this is given to the
mother at the 34 week visit, making clear that this
assessment is additional to the core trial protocol, so
women are free to decline without their participation in
the core trial protocol being affected. Whole body, lum-
bar spine and both hips are measured. The radiation
dose for these scans is: whole body 4.2 μSv, lumbar
spine 4.4 μSv and each hip 2.4 μSv (Hologic Inc., Bed-
ford, MA, USA)
Paediatric follow-up
The children are assessed at 1, 2, 3 and 4 years of age to
characterise diet, health, exercise and anthropometric
measurements. At 4 years the children undergo a repeat
DXA assessment of bone mass at whole body, lumbar
spine, and additionally at hip sites. This will utilise the
same DXA instrument as for the birth measure. If the
family has moved to another location, attempts will be
made to follow the child up and invite them back for
annual follow-up and 4 year DXA assessment. Table 1
summarises the data collected at each time point.
Inclusion and exclusion criteria
Inclusion criteria
• Less than 17 weeks gestation at first assessment
(based on last menstrual period (LMP) and dating
scan)
• Serum 25(OH)-vitamin D concentration is 25-100
nmol/l at nuchal fold/dating scan (10 to 17 weeks
gestation)
• Aged over 18 years
• Singleton pregnancy
• Aiming to give birth at local maternity hospital
Exclusion criteria
• Known metabolic bone disease or chronic disease
known to be associated with bone abnormalities
• Current medication likely to interfere with intrau-
terine growth (corticosteroids, enzyme-inducing
anticonvulsants, PTH, bisphosphonates, more than 6
months GnRH analogues)
• Current use of supplement containing vitamin D
with daily dose > 400 IU
• Foetal physical anomalies on the initial or 18-21
weeks scan (likely to influence bone measurement
by DXA or interfere with skeletal development)
• Inability to provide informed consent or comply
with trial protocol
• History of renal stones, hyperparathyroidism,
hypercalciuria
• A diagnosis of cancer in the last 10 years (other
than basal cell carcinoma)
• Serum calcium > 2.75 mmol/l
Timing and inclusion
Many women do not know accurately when they con-
ceived. Thus gestation based on LMP and that on dating
ultrasound may differ. Therefore women coming for
assessment at 12 weeks may find that they are actually
several weeks earlier or later than this.
• Dating scans may be from 8 weeks; inclusion for
trial is from 8 weeks to 17 weeks gestation.
• Nuchal lucency scanning is not usually possible
before 11 weeks http://www.bmus.org/policies-
guides/SoR-Professional-Working-Standards-guide-
lines.pdf, so any women in earlier gestation is asked
to return at 12 weeks for a repeat scan, and study
medication issue will still be at 14 weeks.
• Women found to be at later gestation (between 13
and 17 weeks) are included and blood taken at the
initial visit by the obstetric team or MAVIDOS
research nurse. Medication is issued at a second visit
as soon as possible after 25(OH)-vitamin D status is
known.
• 14 week visits are acceptable up to anomaly scan;
this scan must be between 18 and 21 weeks to com-
ply with NHS timing.
• 34 week visit acceptable up till delivery.
• Target for 34 week scan is 33 to 36 weeks.
• Postnatal DXA to be performed within 14 days
after delivery.
Sample size and power calculation
Sample size was estimated [Stata V11.0 (Statacorp,
Texas, USA)] using the results from a previous South-
ampton-based mother-offspring cohort (Princess Anne
Hospital Study [13]), in which a difference of 0.42 sd in
whole body bone mineral content was found between
the offspring of mothers who had been vitamin D defi-
cient and those of mothers who had been vitamin D
replete during pregnancy. To detect 50% of the differ-
ence in whole body bone mineral content at birth
between offspring of mothers who were deficient in vita-
min D versus those replete in pregnancy (0.21 sd or 3.5
g), at the 5% significance level with 90% power, would
require recruitment of 477 infants to each arm. Allow-
ing for the expected miscarriage rate and 20% drop-out
rate, we would need to recruit 600 mothers to each
arm. We estimate the prevalence of vitamin D between
25 and 100 nmol/l in the Southampton pregnant popu-
lation to be around 80%, suggesting initial screening of
1,600 women will be required. Pilot data suggest that
around 50% of women who are approached will agree to
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participate in the study; initial invitations will therefore
be sent to 3,200 women.
Around 3500 women attend the Princess Anne Hospi-
tal, Southampton for Down’s screening/dating scan each
year, as part of a national programme involving collec-
tion of serum samples and an ultrasound scan. Previous
experience with the Southampton Women’s Survey sug-
gests a response rate of around 50%, with around 85%
retention through to term pregnancy, with subsequent
DXA assessment of the neonate. Further samples of
3000 incident pregnancies will be available in each of
the other two centres to participate in the trial (Profes-
sor N Bishop, University of Sheffield; Dr S Kennedy,
University of Oxford).
Statistical analysis
It is anticipated that there will be some missing data
during the trial because patients will be lost to follow-
up (non-completers) or will provide incomplete data
(non-compliers). To avoid consequent bias, intention-to-
treat (ITT) analysis will be used, incorporating all
women randomised to either treatment or placebo,
regardless of whether the offspring underwent DXA
assessment at birth. To fully account for participants
whose offspring did not undergo neonatal DXA assess-
ments, we will follow the framework proposed by White
et al. [33] for ITT analysis that depends on making
plausible assumptions about the missing data and
including all participants in sensitivity analyses. Analyses
will be performed using Stata V11.0 (Statacorp, Texas,
USA).
Primary outcome
Whole body bone mineral content of the neonate,
adjusted for gestational age and age at neonatal DXA
scan.
Secondary outcomes
Whole body bone area, bone mineral density, and size-
corrected bone mineral density (BMC adjusted for BA,
length and weight), body composition adjusted for
gestational age and age at DXA scan.
The primary analysis will not be stratified by centre
(Southampton, Sheffield, Oxford) or ethnicity. Tests for
interactions with offspring gender, season of birth,
maternal parity, recruitment centre and ethnicity will
also be performed. Separate analyses will be based on
those participants who completed the protocol, secondly
on those who complied with treatment, thirdly on those
who demonstrated a rise in maternal 25(OH)-vitamin D
concentration and fourthly on those whose initial 25
(OH)-vitamin D level was below 50 or 75 nmol/l.
Table 1 Summary of trial events
12 weeks 14 weeks 34 weeks Delivery 0-14 days
Screening √
Consent √
Maternal height √ √
Maternal weight √ √
Maternal skin folds √ √
Maternal grip strength √ √
Maternal medication √ √
Maternal supplements √ √
Maternal diet √ √
Maternal health √ √
Family health √ √ √
Ultrasound scan √ √
Maternal blood for 25(OH)-vitamin D, Ca, Alb, bALP, DBP
Blood pellet
√ √ √
Maternal urine sample for bone markers √ √
Umbilical venous blood and
Placental tissue
√
Infant urine sample √
Infant length √
Infant weight √
Infant skinfolds √
Infant DXA √
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Statistical tests
The primary outcome is neonatal bone mineral content
as measured by DXA within two weeks following birth,
presented as a continuous variable. The primary com-
parison is treatment (1000 iu cholecalciferol daily) ver-
sus control (placebo capsule daily). Linear regression
modelling (ANOVA) will be used to describe the asso-
ciation of treatment on outcome. Student’s t-tests may
also be used to compare groups in secondary analyses.
Ethical considerations
The study involves the participants undergoing various
procedures with which they may not be familiar.
Detailed information sheets are given to the participants
and they have opportunities to discuss any concerns in
detail with study personnel. The infant DXA assess-
ments are associated with a low dose of radiation expo-
sure equivalent to 2 days background radiation in
Cornwall (UK) or 7 days in other parts of the UK. Data
from the Princess Anne Cohort study showed a small
excess of atopic asthma in children born to mothers
with the highest levels of vitamin D in pregnancy [34].
However the numbers were lower than expected from
the general population and confidence intervals wide.
No associations between atopy in infancy and high levels
of maternal vitamin D have been shown in the South-
ampton Women’s Survey, and other studies have sug-
gested neutral or negative associations [35-37]. The dose
of vitamin D supplementation has been chosen to bring
women just into the normal range, to avoid elevating it
to supranormal levels.
Reporting of adverse events
Anticipated Adverse Events
The development of some infrequent pregnancy-asso-
ciated complications are anticipated to arise sponta-
neously during the study (ie cholestasis of pregnancy,
pregnancy induced hypertension, gestational diabetes,
pre-eclampsia, eclampsia, premature labour or delivery,
instrumental delivery, caesarean section, miscarriage or
stillbirth http://guidance.nice.org.uk/CG62/NICEGui-
dance/pdf/English).
Adverse drug reactions and adverse drug events
Any serious adverse event which is felt in any way to be
related to the IMP is immediately reported (verbally or
in writing) to the sponsor. This is followed by a detailed
written report on the event. The local Principal Investi-
gator decides whether to expedite reports of adverse
events felt to be unrelated to the IMP. A record of all
serious adverse events is kept in the trial master file
regardless of whether reported within 24 hours to the
sponsor.
The sponsor keeps detailed records of all adverse
events relating to a clinical trial which are reported to
them by the investigators for the trial. These records
may be sent to the licensing authority if required.
Suspected unexpected serious adverse reactions
The sponsor ensures that all relevant information about
a suspected unexpected serious adverse reaction which
occurs during the course of the trial and is fatal or life-
threatening is reported as soon as possible to the
MHRA, and the relevant ethics committee/data moni-
toring committee. This is done not later than seven days
after the sponsor was first aware of the reaction. Any
additional relevant information is sent within eight days
of the report.
The sponsor ensures that a suspected unexpected ser-
ious adverse reaction which is not fatal or life-threaten-
ing is reported as soon as possible, and in any event not
later than 15 days after the sponsor is first aware of the
reaction, to the MHRA and the relevant ethics commit-
tee/data monitoring committee.
Monitoring
Trial Steering Committee
Professor David Reid (independent chair), Ms Caroline
Dore (statistician and independent observer), Professor
Cyrus Cooper (chief investigator), Dr Nicholas Harvey
(lead principal investigator), Professor Nick Bishop
(principal investigator), Dr Stephen Kennedy (principal
investigator), Dr Kassim Javaid (principal investigator),
Dr Aris Papageorghiou (principal investigator), Dr Saur-
abh Gandhi (principal investigator), Professor Richard
Eastell (independent member), Dr Zulf Mughal (inde-
pendent member), Mrs Doreen Hedger (lay
representative).
Independent Data Monitoring Committee
Professor Deborah Symmons, Professor Roger Francis,
Dr Mark Philips, Dr Chris Roberts
Regulatory Aspects
The study has received approval from MHRA, South-
ampton and Southwest Hampshire REC, University Hos-
pital Southampton Trust R and D (Sponsor), UHS Data
Protection Office. The IMP and placebos are manufac-
tured in accordance with GMP regulations. The study is
conducted in compliance with the Research Governance
Framework for Health and Social Care, the Medicine for
Human Use (Clinical Trials) Regulation 2004 and GCP.
Indemnity has been provided through University Hospi-
tal Southampton NHS Foundation Trust (sponsor) and
University of Southampton.
Discussion and potential impact
As far as we know, MAVIDOS is one of the first ever
tests, in humans, of the concept that an intervention in
the mother during pregnancy may influence offspring
bone mineral accrual. The result, positive or negative,
Harvey et al. Trials 2012, 13:13
http://www.trialsjournal.com/content/13/1/13
Page 7 of 9
should provide a step change in the evidence guiding
current and future public health policy regarding vita-
min D supplementation in pregnancy. The longer term
follow up of these children will be important because it
is possible that subtle effects of vitamin D supplementa-
tion, such as a reduction in allergy or asthma, will be
only be detected after several years of observation.
Given the current enthusiasm for vitamin D supplemen-
tation, and the possible widespread uptake, it is highly
important that assessment of its effects is not limited
purely to those during and immediately after pregnancy.
Trial Status
The MAVIDOS study is ongoing.
Note
Funding: Arthritis Research UK, Medical Research
Council, Bupa Foundation and NIHR.
ISRCTN82927713, registered 2008 Apr 11. Date first
participant randomised: 2008 Oct 7
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